| Tacrolimus hydrate (FK506): therapeutic effects and selection of responders in the treatment of myasthenia gravis. | |
| | |
MedLine Citation:
|
PMID: 14643908 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Tacrolimus hydrate (FK506) reduces myasthenic symptoms due to its immunosuppressive properties. We studied the therapeutic effects of FK506 and noted improvement in 7 of 13 myasthenic patients on the clinical muscle test (myasthenia gravis, MG score). Two other patients with relapsing ocular symptoms improved. We also examined patient sensitivity to FK506, but could not predict such sensitivity before FK506 treatment in the present study. |
| | |
Authors:
|
Nobuo Wakata; Toyokazu Saito; Sachiko Tanaka; Toshihiko Hirano; Kitaro Oka |
Related Documents
:
|
344998 - Bullous and cicatricial pemphigoid. clinical, histopathologic, and immunopathologic cor... 9366818 - Ovarian malignancy in patients with dermatomyositis and polymyositis: a retrospective a... 1451058 - Malignant transformation in paget disease of bone. 1571478 - Myasthenia gravis with thymoma is not associated with an increased incidence of non-mus... 9296198 - Serial contrast-enhanced mr in patients with multiple sclerosis and varying levels of d... 3337478 - Unsuspected perforation in bleeding duodenal ulcers. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Clinical neurology and neurosurgery Volume: 106 ISSN: 0303-8467 ISO Abbreviation: Clin Neurol Neurosurg Publication Date: 2003 Dec |
Date Detail:
|
Created Date: 2003-12-03 Completed Date: 2004-03-17 Revised Date: 2009-10-14 |
Medline Journal Info:
|
Nlm Unique ID: 7502039 Medline TA: Clin Neurol Neurosurg Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 5-8 Citation Subset: IM |
Affiliation:
|
Fourth Department of Internal Medicine, Toho University School of Medicine, 2-17-6 Oohashi, Meguro-ku, Tokyo 153-8515, Japan. waka@oha.toho-u.ac.jp |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Combined Modality Therapy Female Humans Immunosuppressive Agents / adverse effects, therapeutic use* Male Middle Aged Myasthenia Gravis / diagnosis, drug therapy*, immunology Neurologic Examination / drug effects Patient Selection* Prednisolone / therapeutic use Tacrolimus / adverse effects, therapeutic use* Thymectomy Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Immunosuppressive Agents; 109581-93-3/Tacrolimus; 50-24-8/Prednisolone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Severe myopathy and psychosis in a patient with Cushing's disease macroadenoma.
Next Document: Postoperative communicating hydrocephalus in patients with supratentorial malignant glioma.